Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. scores highest on Torque (65) and lowest on Earnings (20). Its PosiPenta is 42.26 out of 100, around the middle of similar companies.
On the Penta Grid this week, Celldex Therapeutics, Inc. is Grid #460 of 837 in the Healthcare sector in United States, and Grid #2,668 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Celldex Therapeutics, Inc. | 42.26 | 21 | 20 | 57 | 65 | 48 |
| Fortrea Holdings Inc. | 52.56 | 16 | 72 | 96 | 39 | 40 |
| Precigen, Inc. | 40.99 | 1 | 59 | 75 | 6 | 63 |
| Addus HomeCare Corporation | 68.77 | 60 | 68 | 91 | 67 | 57 |
| SELLAS Life Sciences Group, Inc. | 48.58 | 5 | 64 | 71 | 67 | 36 |
| UFP Technologies, Inc. | 61.30 | 34 | 69 | 86 | 63 | 55 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -6.33 |
| P/B ratio | 3.03 |
EEarnings
| Trailing EPS | ₹-412.01 |
| Forward EPS | ₹-401.27 |
NNitro
| Price | 2607.50 |
| 52-week high | 4275.43 |
| 52-week low | 2093.20 |
| Fall from 52-week high | 39.0% |
TTorque
| Return on equity (ROE) | -43.88% |
| Debt-to-equity | 0.01 |
AAnchor
| Beta (price swings) | 0.90 |
| Market cap | ₹20,476 Cr |
| Insider holding | 0.27% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Celldex Therapeutics, Inc.'s PosiPenta score?
Celldex Therapeutics, Inc.'s PosiPenta is 42.26 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Celldex Therapeutics, Inc. stand on the Penta Grid?
On the Penta Grid this week, Celldex Therapeutics, Inc. is Grid #460 of 837 in the Healthcare sector in United States, and Grid #2,668 of 4,000 in United States.
Which PosiPenta pillar is strongest for Celldex Therapeutics, Inc.?
Torque (durability), with a score of 65 out of 100: better than most similar companies.
Which PosiPenta pillar is weakest for Celldex Therapeutics, Inc.?
Earnings (growth), with a score of 20 out of 100: weaker than most similar companies.
Has Celldex Therapeutics, Inc.'s PosiPenta changed since last week?
Yes, it rose 3.00 points, from 39.26 to 42.26.
PositoAI is for research and education only and is not investment advice.